Hepatocellular Carcinoma
Conditions
Interventions
Group 1:conventional TACE
Group 2:cTACEcombined with HAIC
Sponsors
Zhongshan Hospital of Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. clinical or pathological diagnosis of HCC; 2. unresectable stage B / C liver cancer of BCLC; 3. at least one measurable target lesion; 4. ECoG score 0-2; 5. liver function status is child Pugh a or B; 6. the life expectancy shall be at least 3 months; 7. at least 18 years old, no more than 85 years old, gender unlimited; 8. women patients of childbearing age and men patients shall agree to adopt birth control measures since the signing of informed consent; 9. requirements for bone marrow function, liver function and kidney function of patients: (1) Hemoglobin concentration >85 g/L; (2) Peripheral blood WBC >=3x10^9/L; (3) Platelet count >=50x10^9/L; (4) Total bilirubin concentration =28 g/L; (6) ALT and AST <=5 ULN; (7) Prothrombin time international standard ratio (PT-INR) < 2.3 ULN; (8) Serum creatinine <=1.5 ULN.
Exclusion criteria
Exclusion criteria: 1. uncontrollable infection; 2. cholangiocarcinoma or mixed cell carcinoma with other tumors; 3. history of drug allergy; 4. HIV infection; 5. pregnancy; 6. within the first 30 days, patients with severe bleeding symptoms or with a clear tendency of gastrointestinal bleeding (fecal occult blood + + or above can not be included in the group).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival;TTP;ORR;AFP response;DCR;Safety; | — |
Countries
China
Contacts
Public ContactChen Rongxin
Zhongshan Hospital of Fudan University
Outcome results
None listed